Takeda Oncology – Individualized Cancer Care
Awny Farajallah, M.D., Head of Global Medical Affairs Oncology at Takeda, discusses his transition from physician to head of pharma medical affairs and how his unique experience working in infectious disease is advancing Takeda Oncology’s mission to provide individualized cancer care for all patients. Driven to find solutions for disenfranchised people across the globe, Dr. Farajallah’s passion closely aligns with Takeda Oncology’s values and commitment to providing patients the medicine they need, wherever they may be or whoever they may be.
Awny Farajallah, M.D. joined Takeda in July 2021 as the Head of Global Medical Affairs Oncology. He brings over 25 years of combined experience in both academic and industry settings related to clinical research/development and medical affairs across multiple therapeutic areas.
Awny joins Takeda from Ipsen, where he was Senior Vice President, Medical Affairs, North America. As a key North America Leadership Team and Global Medical Affairs Leadership Team member, Awny was responsible for providing strategic leadership and direction for all facets of the Medical Affairs organization in North America. During his tenure, Awny also led efforts to enhance Medical Affairs capabilities with the goal of broadening the impact to patients through medical stakeholder partnerships across Oncology, Neuroscience and Rare Disease.
Prior to joining Ipsen, Awny served as Vice President and Head of US Medical Affairs at Bristol Myers Squibb, where he led functions such as field medical, disease areas, medical education, biomarkers, promotional material review, portfolio strategy, as well as strategic collaborations across oncology, immunoscience, cardiovascular, neurology and mature brands. Awny has led multiple successful launches in Immuno-oncology and hematology for Opdivo ® and Yervoy ® and Sprycel ®. He also was the clinical development lead for hematological malignancies in leukemia and multiple myeloma. He also led the global medical and clinical development teams for HIV including Reyataz ® global life cycle management and business development.
Awny earned his M.D. from Cairo Univ
